ClinicalTrials.gg
RecruitingNCT05840042Updated Oct 13, 2026

Epidemiology and Risk Factors of Uterine Fibroids in China

An observational study in Uterine Fibroid, sponsored by Wenwen Wang. Recruiting at 1 site in China. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Wenwen Wang · Observational

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.
Updated Oct 13, 2026Now RecruitingFirst site in China+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20,000
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Leiomyoma with a site in China — 20 open to participants now, 23 under way, 2 of them phase 3. Leiomyoma · China.

Planned enrollment
Largest of 11
20,000 · median 200
Started
2023
with 4 others
Observational
11 of 40
8 open now
Primary completion
2026-12
later than 14 of 22 live
Registered
18th of 40
by date
Lead sponsor
3 of 40
Wenwen Wang

Among the 40 studies in Leiomyoma with a site in China, this one has the largest planned enrollment of the 11 observational ones that give a count, is one of 5 that started in 2023, is one of 11 observational ones, reaches primary completion later than 14 of the 22 other live ones, and was the 18th registered.

Leiomyoma

438 studies on the registry are indexed under Leiomyoma; 74 are open to participants now.

Browse Leiomyoma studies →

Open to participants now

20 of the 40 studies in Leiomyoma with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 44 Leiomyoma studies recruiting now, 23 (52%) set no upper age limit and 20 (45%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Leiomyoma with a site in China, or all of them as a file.
02

Study summary

Uterine fibroids are the most common form of benign uterine tumors in the uterine muscle layer, which had a certain rate of malignancy, but it is rare. The prevalence of uterine fibroids estimates range from 4.5% to 68.6% depending on study population and diagnostic methodology. The prevalence of fibroids has been historically underestimated by epidemiologic studies which focused mainly on symptomatic women, leaving behind a large population of asymptomatic women and women who underreport their symptoms. What investigators don't know was which women who have fibroids will develop clinical symptoms and which women who have an operation of myomectomy will relapse. The purpose of this study is to investigate the prevalence, incidence and risk factors for the development of uterine fibroids in Chinese women.

03

Conditions studied

  • Uterine Fibroid

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

This study population is women aged more than 18yrs with or without uterine fibroids from five regions of China. The study time period will conduct from May 1, 2023 - November 30, 2025 to allow for 6 months pre-index for evaluating baseline demographic and clinical characteristics and 24 months post-index, ensuring a minimum of one years follow-up.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Current place of residence≥ 6 months;
  • No serious mental illness or mental abnormality;
  • Those who agree to participate in this survey and cooperate in completing the questionnaire.

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Prevalence of uterine fibroids in China

    Prevalence of uterine fibroids in China

    Time frame: Baseline

Secondary outcomes

  1. Incidence of uterine fibroids in China

    Incidence of uterine fibroids in China

    Time frame: Two follow-ups over a three-year period

  2. Risk factors of development of uterine fibroids in China

    Associated risk factors for recurrence, infertility and malignancy of uterine fibroids in China

    Time frame: Two follow-ups over a three-year period

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Yan W, Yuan S, Zhou D, Zhang M, Yang S, Wang W, Wang S. Status and treatment of patients with uterine fibroids in hospitals in central China: a retrospective study from 2018 to 2021. BMJ Open. 2024 Jan 17;14(1):e081736. doi: 10.1136/bmjopen-2023-081736. PubMed 38233053 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Dec 2026, 42 months after the start.

Of 45 observational studies under Leiomyoma, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 99. This study's planned 42 months is above that.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2025 → Dec 2026, on Oct 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2023
First posted
May 3, 2023
StartActual
Jun 19, 2023
Primary completionEst.
Dec 31, 2026was Dec 2025
CompletionEst.
Dec 31, 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 13, 2026
Sites
1 site added — first site in China
Show site
  • Huazhong University of Science and Technology · Wuhan, China
Oct 13, 2026
Primary completion
Dec 31, 2025→Dec 31, 2026
Oct 13, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 38233053 ↗
Oct 13, 2026
Sponsor
Shixuan Wang→Wenwen Wang; Collaborators added: The Fourth Hospital of Shijiazhuang; collaborators removed: Fourth Hospital of Shijiazhuang City
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Not yet recruiting→Recruiting
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 38233053 ↗
    1 site added — first site in China
    Show site
    • Huazhong University of Science and Technology · Wuhan, China
    Primary completion Dec 31, 2025→Dec 31, 2026
    Sponsor Shixuan Wang→Wenwen Wang; Collaborators added: The Fourth Hospital of Shijiazhuang; collaborators removed: Fourth Hospital of Shijiazhuang City
    + 3 other changes: index terms, verification date and criteria formatting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05840042
Lead sponsor
Wenwen Wang
Collaborators
Women's Hospital School Of Medicine Zhejiang University, Tongji Hospital, First Affiliated Hospital, Sun Yat-Sen University, West China Hospital, The Fourth Hospital of Shijiazhuang
Responsible party
Wenwen Wang (Professor, Tongji Hospital) — Sponsor-investigator
First posted
May 3, 2023
Start date
Jun 19, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 13, 2026

Study contacts

WENWEN WANG, DOCTOR
Contact
petrawang@163.com
15927167698
MINLI ZHANG, MASTER
Contact
SHIXUAN WANG, DOCTOR
principal investigator · Huazhong University of Science and Technology

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion